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Abstract 
Introduction: Community-acquired pneumonia is the most common infection 
leading to hospitalization and death in all age groups, especially in elderly 
populations. Increasing antibiotic resistance among the common bacterial pathogens 
associated with community-acquired pneumonia, especially Streptococcus 
pneumoniae and staphylococci, has made its empirical treatment increasingly 
problematic, highlighting the need for effective antibiotic therapy. 
Areas covered: We searched PubMed and ClinicalTrials.gov for English-language 
reports of phase III clinical trials conducted between 2000 and 2019 concerning the 
antibiotic treatment of community-acquired pneumonia. We provide a summary of 
the latest approved drugs for this indication and highlight emerging drugs with a 
potential indication. 
Expert opinion: Ceftaroline (a new cephalosporine) and omadacycline (a cycline 
alternative), either parenterally or orally, are the only two new antibiotics to have 
been approved by the FDA for the treatment of community-acquired pneumonia in 
the last five years. Among the antimicrobials in development, Lefamulin (the first 
pleuromutilin), is currently in phase III development. Among the known antibiotic 
classes, solithromycin (a macrolide), nemonoxacin (a quinolone), and delafloxacin 
and zabofloxacin (both fluoroquinolones), have been studied in phase II and III in 
clinical trials. The availability of these new antibiotics may offer opportunities to 
improve the empirical treatment for community-acquired pneumonia. 
Keywords: Community acquired pneumonia, emerging, antibiotics, omadacycline, 
lefamulin, solythromycin 
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1. Background 
Community-acquired pneumonia (CAP) remains an important worldwide health 
problem. It is responsible for hospitalization, re-admissions, pulmonary and extra-
pulmonary complications, and short- and long-term mortality [1, 2, 3]. The clinical 
presentation of CAP ranges from mild or localized to severe or systemic disease, 
which may be associated with complications such as sepsis, septic shock, and 
respiratory failure, even leading to multiple organ dysfunction and death. CAP is 
especially dangerous in elderly and immunocompromised patients, in whom the 
mortality rate can reach 20%–40%, which is significantly higher than the 6%–10% 
reported for the general population [4, 5]. 
Recently, investigations have focused on the increasing prevalence of antibiotic-
resistant pathogens causing CAP, especially in severe cases [6, 7, 8], and on the 
relation between cell-mediated immunity and the inflammatory response to 
pneumonia [9, 10]. Streptococcus pneumoniae remains the main causative pathogen 
in CAP [11], despite studies indicating that respiratory viruses play an important role 
[12, 13]. However, a small proportion (6%) are caused by multidrug-resistant (MDR) 
pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), 
Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. 
The antibiotic resistance of these pathogens makes them a challenge for clinical 
management and a key global public health concern. 
The development of molecular diagnostic techniques over the last three decades has 
led to the importance of respiratory viruses being emphasized as causes of CAP and 
its associated mortality worldwide. Indeed, approximately 20%–30% of patients 
hospitalized with viral CAP are estimated to need intensive care unit admission. 
Recently, our group [11] reported that viral sepsis was present in 19% of patients 
admitted to intensive care with CAP, with influenza viruses being most common, and 
males and older patients being at greatest risk. An interesting recent study by Zhou 
et al. [12] that investigated non-influenza viruses causing CAP showed that 63%, 
26%, and 10% of cases were caused by influenza viruses, non-influenza viruses, 
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and mixed viral infections, respectively. The authors found that complications were 
common in patients with non-influenza CAP, but that outcomes were similar to those 
in patients with influenza. Together, these data support the importance of respiratory 
viruses as causes of CAP. 
There is an urgent clinical need for effective antimicrobial therapy to treat the range 
of etiologies of CAP, especially in terms of improving the initial therapy given to 
patients with MDR pathogens. In this review, new antibiotics belonging to both old 
and new antibiotic classes will be analyzed and discussed with these considerations 
in mind. 
 
2. Methods 
The PubMed database was searched using the following search string: “Pneumonia” 
AND English AND (“Community-acquired” OR “Community acquired” OR “CAP” OR 
“Hospitalized” OR “Hospitalized”) AND (“Antibiotics” OR “Antimicrobial” OR 
“Resistance” OR “Anti-Bacterial Agents” OR “Antiviral Agents”). Search results were 
restricted to clinical trials, meta-analyses, observational studies, and systematic 
reviews. Titles and abstracts were initially screened to identify relevant citations, and 
these were then reviewed in full by two authors. We included all publications 
presenting data on CAP, and reviewed the study setting, methodology, and 
characteristics of the study population. All authors confirmed that the inclusion of the 
identified publications was appropriate. 
 
3. Existing Treatment Options and Needs 
3.1 Antibiotics  
Antibiotic resistance in S. pneumoniae (pneumococcus), the main pathogen 
responsible for CAP, is a major global concern. The emergence of MDR 
pneumococcus due to overuse of antibiotics is a global concern that affects the main 
anti-pneumococcus drugs, β-lactams, macrolides, and fluoroquinolones. Last year a 
study about the burden of pneumococcal CAP in adults across Europe [1] showed 
that the overall incidence was 68–7000 per 100,000 and the incidence in 
hospitalized CAP cases was 16–3581 per 100,000. The authors reported that the 
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incidence increased with age, and that the greatest impact was observed in patients 
with more comorbidities. Interestingly, a study published by our group. [14] about the 
20-year trend in mortality due to pneumococcal CAP in 1120 hospitalized adults in 
Spain failed to show any decrease in mortality over time. The recent report by the 
SENTRY Antimicrobial Surveillance Program [15] evaluated antimicrobial 
susceptibility for S. pneumoniae isolates worldwide over a 20-year period (1997–
2016) indicated that MDR and extensively drug resistant isolates varied by region. 
The Asia–Pacific region showed the highest rates (41% in 1997–1998; 53% in 2007–
2008; 39% in 2015–2016), whereas Latin America presented the lowest rates (10% 
overall). In North America, the data showed an increase from 9% in 1997–1998 to 
24% in 2009–2010, followed by a decrease to 17% in 2015–2016. An increase was 
also seen in Europe from 17% in 1997–1998 to 24% in 2007–2008, but this also 
decreased in the last period (19% in 2015–2016). 
The PES pathogen group (i.e., P. aeruginosa, extended-spectrum β-lactamase 
Enterobacteriaceae, and methicillin-resistant S. aureus) cause approximately 6% of 
cases of CAP [16]. Among them, P. aeruginosa and MRSA are the most frequently 
reported, and they require different antimicrobial therapy compared with typical 
pathogens. A recent multinational point-prevalence study [17] presented data from 
3193 patients with CAP in 222 hospitals from 54 countries and reported the burden 
and risk factors associated with P. aeruginosa infection. The study showed that there 
was a low prevalence of CAP caused by P. aeruginosa (4%), corresponding to only 
11% of patients with culture-positive pneumonia. The prevalence rates of antibiotic-
resistant and MDR P. aeruginosa were also low at 2% and 1% respectively. By 
continent, the prevalence of P. aeruginosa in CAP was as follows: 3.8% in Europe, 
4.3% in North America, 5.2% in Asia, 4.9% in South America, 5.5% in Africa, and 
3.1% in Oceania. The corresponding prevalence of antibiotic-resistant P. aeruginosa 
was 1.6% (MDR, 0.9%) in Europe, 2.5% (MDR, 1.2%) in North America, 2.2% (MDR, 
0.5%) in Asia, 3.0% (MDR, 2%) in South America, and 3.9% (MDR, 2.3%) in Africa, 
with no reported cases of P. aeruginosa antibiotic resistance in Oceania. Similarly, a 
Spanish prospective cohort study [18] into the clinical outcomes and risk factors for 
MDR and non-MDR P. aeruginosa reported a prevalence of 1.1% for MDR P. 
aeruginosa among 2023 culture-positive patients. CAP due to P. aeruginosa was 
shown to be an individual risk factor for mortality in that study population. 
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In two independent European studies of patients hospitalized with CAP, it was 
reported that MDR pathogens were causative in 3.3% (a Spanish cohort) and 7.6% 
(an Italian cohort), with MRSA pathogens being most common [8, 19]. The Global 
initiative for MRSA pneumonia (GLIMP) analyzed data for 3191 patients receiving 
microbiological tests within 24 h of admission for CAP and reported a 3% global 
incidence for MRSA as a cause. Risk factors for MRSA in CAP were prior MRSA 
infection or colonization, recurrent skin infection, and severe pneumonia. Other 
studies in the USA have reported incidence rates of 0.7%–2.4% [20, 21].  
A. baumannii has been considered a rare cause of CAP, but one that retains clinical 
relevance. The great majority of CAP cases caused by A. baumannii are reported in 
tropical or sub-tropical countries, principally in Asia-Pacific regions, with the highest 
prevalence in Hong Kong, Singapore, Taiwan, South Korea, and Australia [22, 23]. 
In Europe and North America, however, A. baumannii is exceedingly rare. A recent 
USA report found that only 19 cases of severe CAP were caused by this pathogen 
[24]. Interestingly, in a case-control study in the USA that aimed to characterize the 
epidemiology of MDR A. baumannii colonization in high-risk nursing home residents, 
15% (n = 25) of residents were noted to be colonized, with all isolates being resistant 
to cephalosporins, monobactam (aztreonam), and quinolones. They reported the 
main risk factors for MDR A. baumannii as functional disability, Proteus mirabilis 
colonization, and diabetes mellitus [25]. 
CAP caused by K. pneumoniae is reported in approximately 1%–7% of cases [8], 
with MDR strains accounting for only  5%–36%. In Asian countries, such as Taiwan, 
Cambodia, and Shanghai, K. pneumoniae has been described as a frequent cause 
of bacteremia [26, 27]. By contrast, CAP caused by K. pneumoniae is generally rare 
in Europe and USA, despite there being an increasing incidence in these regions 
over recent years [28, 29]. 
Empirical antibiotic therapy for severe CAP remains based on international 
guidelines that recommend a macrolide or a respiratory fluoroquinolone in 
combination with a β-lactam, with coverage for PES pathogens only given when 
certain risk factors are present. The research and development of new antibiotics is 
scientifically and economically challenging, yet this must remain a key goal given 
current global needs and the spread of antimicrobial resistance. Given that antibiotic 
therapies for MRSA and P. aeruginosa differ from typical empirical therapy, we must 
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recognize the risk factors and local epidemiology relevant to these resistant 
microorganisms in clinical contexts. Early recognition and prompt initiation of broad-
spectrum empirical antibiotic therapy is mandatory to limit the negative effects of 
these pathogens, but this is limited by a decline in the production of new antibiotics 
and a failure to keep pace with epidemiological changes over recent decades. 
Arguably the most important consideration with these new antimicrobials is that they 
should be broad spectrum to allow clinicians to treat CAP in the era of increasing 
resistance. 
 
3.2 Antivirals  
Currently, neuraminidase inhibitors (e. g., oseltamivir, zanamivir, peramivir) are well 
established in clinical practice for use in patients with influenza infection, but no 
randomized-controlled trial (RCT) of has been completed to confirm the efficacy of 
these antivirals in hospitalized patients. The data of several prospective 
observational studies and meta-analysis indicate that neuraminidase inhibitor 
therapy at the time of hospitalization reduces both the length of hospitalization and 
the related mortality [30, 31]. The main problem with neuraminidase inhibitors like 
oseltamivir, however, is the need for early treatment. Other antivirals approved by 
the Food and Drug Administration (FDA) include adamantanes (e.g., amantadine 
and rimantadine) are not recommended because of widespread resistance. The 
polymerase inhibitors baloxavir marboxil and favipiravir have shown efficacy against 
influenza A and B, and against strains resistant to neuraminidase inhibitors, but is 
known about their resistance profiles.  
During influenza seasons, respiratory syncytial virus (RSV) is a major cause of 
moderate-to-severe respiratory infection, especially in immunocompromised 
patients. Ribavirin is the only approved treatment option for RSV, but this antiviral 
suffers from its limited efficacy and propensity for genotoxicity. 
 
4. Market review and current research goals 
The increase in antimicrobial resistance has led to the development of new 
antibiotics in recent years, with may being approved for the treatment of pneumonia. 
Unfortunately, the development of new resistant bacterial strains has outstripped this 
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development because of high costs, long drug development times, and difficulties in 
designing and performing adequate trials. A current estimate is that fewer than 10 of 
the 50 leading pharmaceutical companies have active antimicrobial drug 
development programs [32]. 
Omadacycline, is a modernized tetracycline that was specifically designed to 
overcome tetracycline resistance. It received FDA approval in October 2018 for the 
treatment of bacterial CAP and acute bacterial skin and skin structure infections 
(ABSSSIs). Most agents detailed in this text have primarily been designed to treat 
infections caused by MRSA, but these have only proven secondarily to be active 
against MDR S. Pneumoniae. New lipoglycopeptides (e.g., dalbavancin, oritavancin, 
and telavancin) and oxazolidinones (e.g., tedizolid) are therefore attractive options 
for treating infections due to gram-positive MDR bacteria [33,34]. 
Unlike MRSA, research and development into novel drug candidates for gram-
negative resistant bacteria, especially extended spectrum beta-lactamase inhibitors 
or carbapenem-resistant Enterobacteriaceae, will take longer and incur higher costs. 
Despite this clear need for novel antibiotics without the potential cross-resistance, no 
new drug classes are close to market entry. Two new cephalosporins with or without 
a β-lactamase inhibitor have been approved for such infection, just not for CAP: 
ceftolozane with tazobactam and ceftazidime with avibactam. 
This situation is by no means new. Indeed, nearly all antibiotic classes in use today 
were discovered during the Golden Age of antibiotic innovation in the 1940s and 
1960s [32]. Efforts to modify the chemical structures then focused on circumventing 
emerging class-specific target or drug-modifying resistance mechanisms, or to lower 
the affinity for efflux pumps, as well as on improving the pharmacokinetics and 
extending the spectrum of activity. The holy grail of antibiotic progress—a truly novel 
class of antibiotics—has not been achieved since 1987, and current economic 
incentives will likely continue this trend. A major hope lies with several biological 
agents, mainly monoclonal antibodies, which are in phase I or II development for use 
as adjunctive therapy in staphylococcal infections (e.g., 514G3, AR-301, DSTA-
46375, suvratoxumab, SAL-200, ASN-100, and CF-301). 
Numerous agencies and professional societies have tried to draw attention to the 
lack of new antibiotics, especially for the treatment of MDR gram-negative 
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pathogens. Since January 2012, when the Generating Antibiotic Incentives Now 
(GAIN) act came into effect in the USA, development of a new antibiotic agent that is 
active against one or several pathogens on a central list allows a Qualified Infectious 
Disease Product (QIDP) designation to be obtained [35]. Consequently, the overall 
USA budget to fight antimicrobial resistance almost doubled to about 1.2 billion 
dollars by 2016, with more antibacterial molecules clearly being approved in recent 
years. 
 
5. Newly approved antibiotics and drugs in development 
Newly approved and phase III drugs against gram-positive and gram-negative 
bacteria are described in Table 1. There are also a number of promising antibiotics in 
development that should be able to widen the therapeutic armament against difficult-
to-treat gram-positive infections. Solithromycin, delafloxacin, zabofloxacin, and 
nemonoxacin have each demonstrated broad-spectrum antibacterial activity, 
together with other beneficial features such as intracellular accumulation, anti-
inflammatory effects, and inhibition of biofilm production. A new drug, lefamulin, is a 
pleuromutilin antibiotic that is currently in phase III of development. 
In this section we look at the main drugs showing potential in each of the main drug 
classes. 
 
5.1. Cephalosporins: the potential of ceftaroline  
The cephalosporins are known for their broad spectrum of activity, proven efficiency, 
and favorable safety profile, making them among the most commonly prescribed 
antimicrobials. Ceftobiprole and ceftaroline are particularly noted for their activity 
against MRSA and MDR S. Pneumoniae, but only ceftaroline is approved by the 
FDA in the treatment of CAP [36].  
Ceftaroline (Teflaro® in the USA and Zinforo® in Europe) is a fifth-generation 
cephalosporin with an in vitro spectrum of activity that includes most of the common 
bacterial pathogens associated with CAP. It has bactericidal activity against MDR S. 
pneumoniae, non-extended-spectrum β-lactamase producing K. pneumoniae, and 
Escherichia coli, and its high affinity for PBP2a grants coverage against MRSA [37]. 
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In vitro and in vivo animal models: The effect of ceftaroline in both combination 
therapy and monotherapy has been examined in multiple in vitro pharmacokinetic 
models. It has been used in combination with daptomycin, vancomycin, and rifampin. 
Ceftaroline and daptomycin both provide activity against MRSA, and ceftaroline 
increases the binding of daptomycin. B-lactams are used in combination with 
vancomycin due to the seesaw effect, an in vitro phenomenon where, as daptomycin 
and vancomycin minimum inhibitory concentations (MICs) increase in MRSA, the 
MICs of β-lactams, including ceftaroline, decrease [38]. 
However, both low-level  and high-level  resistance to ceftaroline have been 
observed in MRSA strains; particularly concerning are recent reports of resistance 
discovered in clinical MRSA isolates from patients in geographic regions never 
exposed to the drug [39]. Little is known of ceftaroline's ecological impact, though it 
is expected to be minor, as the drug is not excreted in the faeces. 
The approval of ceftaroline for the treatment of CAP was based on two phase III 
multinational RCTs conducted in hospitalized patients: FOCUS 1 (NCT00621504) 
and FOCUS 2 (NCT00509106). In these, 600 mg ceftaroline fosamil was given every 
12 h and demonstrated noninferiority to 1 g ceftriaxone every 24 h, but with 
differences in clinical cure rates at the test-of-cure visit favoring ceftaroline fosamil in 
each trial [40,41]. With ceftaroline, clinical cure was achieved in up to 80% of cases 
and the agent was well tolerated, with only mild adverse events (e.g., diarrhea, 
headache, and insomnia). How ver, neither study included patients admitted to 
intensive care or who had comorbidities, and there were few MDR S. pneumoniae (n 
≤ 10) and MRSA (n = 1) isolates. Analysis of data from the FOCUS trials showed 
that ceftaroline was still associated with a shorter time to clinical response than 
ceftriaxone [42]. Although there are no data from RCTs supporting the use of 
ceftaroline fosamil for MRSA pneumonia, some research supports its efficacy in 
cases of MRSA bacteremia, MRSA endocarditis, and CAP [43,44].  
Ceftaroline appeared to be well tolerated in these trials, but several post-marketing 
reports of severe myelotoxicity associated with prolonged exposure (>7 days) to 
ceftaroline have emerged [45]. At present, it is approved by the FDA and the 
European Medicines Agency (EMA) for the treatment of both CAP and complicated 
skin and skin structure infections [46]. 
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5.2. Tetracyclines: the potential of omadacycline 
Tetracyclines are a group of broad-spectrum antibiotics whose general usefulness 
has reduced with the onset of bacterial resistance. Despite this, they remain the 
treatment of choice for CAP due to their effectiveness against atypical bacteria. 
Omadacycline is the lead compound of the novel aminomethylcycline subclass of 
tetracyclines. Similar to tetracyclines, omadacycline acts by inhibiting protein 
synthesis, but binds to 70 S ribosomes with greater affinity than tetracycline. The 
modification in the C-9 position arose from the finding that tigecycline, a C-9 
substituted semisynthetic derivative of minocycline, was not affected by the most 
common resistance mechanisms, namely efflux and ribosomal protection, despite 
retaining clinical activity [47]. It is a broad-spectrum antibiotic with improved activity 
against tetracycline-resistant pathogens, including methicillin-susceptible S. aureus 
and MRSA, as well as various streptococci and enterococci. It is also more active 
than doxycycline and minocycline against Enterobacteriaceae and A. baumannii, 
with MICs of <4 μg/mL for 90% of strains [48]. Omadacycline is also active against 
many clinically important Enterobacteriaceae and a wide range of anaerobes [49], 
including the atypical organisms Legionella pneumophila, Mycoplasma pneumoniae, 
and Chlamydia pneumoniae.  
Of clinical importance, omadacycline has also shown promise against fast-growing 
mycobacteria in a comparison with tigecycline and doxycycline, where it was 
demonstrated that omadacycline and tigecycline had similar activities against M. 
abscessus, (MIC50 of 1 μg/mL and MIC90 of 2 μg/mL. Against M. chelonae, the MIC50 
values for omadacycline and tigecycline were 0.125 μg/mL and 0.06 μg/mL, 
respectively, indicating that the latter was superior; however, both drugs had the 
same MIC90 of 0.25μg/mL [50]. This notwithstanding, omadacycline has 
pharmacokinetic advantages of higher and more sustained concentrations in the 
plasma and epithelial lining fluid (ELF)compared with tigecycline, suggesting that it 
may be a promising antibacterial agent for the treatment of CAP caused by 
susceptible pathogens [51]. 
In the US, omadacycline was approved in October 2018 for the treatment of bacterial 
CAP and ABSSSIs  . It is taken once daily, which offers an advantage over 
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minocycline and doxycycline, and is available in both oral and intravenous forms as 
a tosylate salt. However, its oral bioavailability is only 35%, with food reducing the 
oral bioavailability. It should therefore be administered in the fasted state. It is 20% 
protein bound in the serum and has a biologic half-life of 17 h [52].  
The use of omadacycline was based on the results of a 750-patient phase III RCT 
(OPTIC Trial) that compared oral or intravenous omadacycline to oral or intravenous 
moxifloxacin for the treatment of mild, moderate, and severe bacterial CAP from 
November 2015 [53]. Patients were given 100 mg intravenous omadacycline twice a 
day (two doses), followed by 100 mg daily, intravenously, or 400 mg intravenous 
moxifloxacin once a day for three days. In both cases, there was an option to switch 
to oral administration. Omadacycline was statistically non-inferior to moxifloxacin for 
early clinical response, with rates of 81.1% and 82.7%, respectively [54]. Even 
though omadacycline had slightly lower success rates with S. aureus, it was still 
considered non-inferior to moxifloxacin [55]. Unfortunately, patients with severe CAP 
(graded class V in the Fine score) or those who presented in septic shock were 
excluded. Gastrointestinal side effects were also greater with omadacycline [56]. 
 
5.3. The ketolides: solithromycin, a next-generation macrolide 
Solithromycin is the first next-generation macrolide of the fluoroketolide class [57]. 
Drug-binding studies indicate that it interacts with the 50S ribosomal site that either 
coincides or overlaps with that of other macrolides and ketolide [58]. Solithromycin 
binds to three distinct sites on the ribosome, whereas telithromycin binds to two 
sites. In terms of resistance selection, solithromycin has demonstrated a low 
tendency to select for resistant mutants, with little or no yields being detected in 
single-step studies [59]. In addition, it has potent in vitro activity against the most 
common bacterial pathogens in CAP, including macrolide-, penicillin-, and 
fluoroquinolone- resistant S. pneumoniae isolates, as well as Haemophilus 
influenzae and atypical bacteria. 
Pharmacodynamically, solithromycin is 16-times more potent than either 
azithromycin, clarithromycin, or telithromycin against gram-positive aerobes and both 
atypical and gram-negative CAP pathogens [58]. It has good oral bioavailability 
(67%) when given orally and is not influenced by concomitant food intake, it serum 
Ac
ce
pte
d M
an
us
cri
pt
 
protein binding is 81%, and its biologic half-life of 8.5 h, allowing once daily dosing 
[60]. The major metabolic pathway appears to involve cytochrome P450 (CYP) 3A4, 
with most of the metabolite undergoing biliary excretion[61]. 
A phase II trial evaluated the safety and efficacy of solithromycin in the treatment of 
bacterial CAP (ClinicalTrials.gov registration no. NCT01168713) for the treatment of 
uncomplicated urogenital gonorrhea [62]. Recently, two phase III RCTs were 
completed for the treatment of mild-to-moderate bacterial CAP (NCT01968733 and 
NCT01756339). Solithromycin demonstrated noninferiority to moxifloxacin within 72 
h, meeting the FDAs primary endpoint, but was inferior at 5–10 days, as required by 
the EMA. The efficacy and safety of oral solithromycin versus oral moxifloxacin in the 
treatment of bacterial CAP was also assessed in a global noninferiority RCT [63]. In 
the separate SOLITAIRE-IV phase III trial, the efficacy and safety of intravenous-to-
oral solithromycin was assessed against intravenous-to-oral moxifloxacin for the 
treatment of bacterial CAP [64]. All patients began treatment with 400 mg 
intravenous solithromycin or moxifloxacin before switching to oral dosing when 
clinically indicated for a total treatment duration of 7 days. Oral dosing was 800 mg 
daily then 400 mg daily for solithromycin, or 400 mg daily for moxifloxacin. In this, 
79.3% of patients who received solithromycin showed early clinical response 
compared with 79.7% of patients who received moxifloxacin. Finally, solithromycin is 
being tested in a phase II/III pivotal trial for bacterial CAP in a pediatric cohort (age 2 
months to 17 years) (NCT02605122). 
It appears that solithromycin does cause more adverse events (34%; mainly at the 
infusion site) compared with moxifloxacin (13%), though it does not prolong the 
cardiac QT interval. Solithromycin is chemically and biologically differentiated from 
telithromycin by its side chain, which does not significantly block nicotinic 
acetylcholine receptors. This could potentially reduce blurry vision, exacerbations of 
myasthenia gravis, loss of consciousness, and idiosyncratic hepatic failure reported 
with ketolides [65]. Nevertheless, hepatic safety remains a concern, with 5%–10% of 
patients experiencing mild transaminase elevations. Given the relatively small 
sample sizes in which solithromycin was studied, the FDA believes this may 
underestimate this particular safety risk. For this reason, on December 29th, 2016, 
the FDA recommended further studies, increasing the number of exposed patients 
from 924 to approximately 12,000 in an effort to evaluate the risk of hepatic toxicity 
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before formally granting approval [66, 67]. 
 
5.4. Quinolones: nemonoxacin, zabofloxacin, and delafloxacin 
The quinolones levofloxacin and moxifloxacin have both been applied in the 
treatment of CAP, with each having antibacterial efficacy against major gram-positive 
and gram-negative respiratory tract pathogens. Novel quinolones therefore hold 
promise for the treatment of CAP even though fluoroquinolone resistant gram-
negative and gram-positive respiratory tract pathogens are detected worldwide [68]. 
 
5.4.1 Nemonoxacin 
Nemonoxacin is a novel C-8-methoxy non-fluorinated quinolone that targets DNA 
gyrase and topoisomerase IV, having a broader profile of activity and reduced 
resistance profile compared with other fluoroquinolones. TaiGen in-licensed 
nemonoxacin from Procter & Gamble Healthcare in 2011, when it obtained 
worldwide rights [69]. The drug benefits from a broad spectrum of activity against 
gram-positive, gram-negative, and atypical pathogens, including activity against 
MRSA (MIC90 = 1 μg/mL) and vancomycin-resistant pathogens, with similar activity 
to levofloxacin and moxifloxacin against most gram-negative bacteria [70]. It has also 
been shown to exhibit the best in vitro activity against Nocardia spp. among all 
tested antibiotics, including fluoroquinolones, carbapenems, tigecycline, and linezolid 
[71]. However, it exhibits poor activity against both MDR and non-MDR strains of 
Mycobacterium tuberculosis. 
According to pharmacokinetic studies, the oral absorption of 500 mg nemonoxacin is 
rapid [70]. It has a mean time to maximum plasma concentration of 1–2 h, a half-life 
of 12.83–18.56 h, and a near 100% bioavailability. Moreover, it has low serum 
protein binding (16%) and no known interaction with cytochrome P450 isoenzymes, 
giving it minimal potential drug-drug interactions. Food significantly decreases both 
the maximum serum concentration (by 34%–46%) and the area under the curve (by 
18%–27%) but increases the time to maximum serum concentration (by two- to 
three-fold). It is available in both oral and intravenous forms. 
To date, phase II and III trials have compared oral formulations of nemonoxacin with 
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levofloxacin, but only a phase II trial has compared intravenous formulations of 
nemonoxacin with moxifloxacin. Despite these being complete, only one phase II trial 
of oral nemonoxacin has been published [72,73]. In a recent phase III noninferiority 
RCT in Taiwan, the efficacy and safety of nemonoxacin was compared with 
levofloxacin in 532 adults (≥ 70 years old) with mildly to moderately severe CAP 
(PORT scores II-IV) [74]. This showed nemonoxacin to be non-inferior to 
levofloxacin, with clinical cure rates of 94% in both groups and a favorable safety 
profile for nemonoxacin (adverse events of the gastrointestinal and nervous systems 
were most common). A second phase III multicenter, noninferiority RCT has 
completed enrollment and publication is anticipated (NCT02205112) [75]. 
In Taiwan, an oral formulation of nemonoxacin was approved in March 2014 for the 
treatment of bacterial CAP, and it had reached market in Taiwan, Russia, the 
Commonwealth of Independent States, Turkey, mainland China, and Latin America 
(brand name Taigexyn) by the end of 2016 [76]. It has already received priority 
review status by the FDA as a QIDP once further phase III studies are available 
documenting its safety and efficacy. 
 
5.4.2 Zabofloxacin 
Zabofloxacin is a broad-spectrum fluoroquinolone manufactured by Dong Wha 
Pharm. Co., Ltd. (Seoul, Republic of Korea). It has proven bactericidal efficacy both 
in vitro and in vivo against major gram-positive and gram-negative community-
acquired pathogens of the respiratory tract, including S. pneumoniae, S. aureus, H. 
influenzae, and M. catarrhalis. By contrast, zabofloxacin has no activity against 
major pathogens associated with nosocomial pneumonia, such as P. aeruginosa and 
A. baumannii [77, 78]. The support for zabofloxacin’s antibacterial efficacy and 
information about its pharmacokinetic profile have been gathered from three clinical 
trials. In a phase III, noninferiority RCT efficacy of 367 mg oral zabofloxacin once 
daily for 5 days was comparable to 400 mg moxifloxacin once daily for 7 days [79]. In 
a phase II RCT of the safety and efficacy of 400 mg oral zabofloxacin for 5 days 
compared to 500 mg oral levofloxacin for 7 days in CAP was terminated in 2012. 
 
5.4.3 Delafloxacin 
Ac
ce
pte
d M
an
us
cri
pt
 
Delafloxacin, currently marketed as Baxdela in the US, is a fluoroquinolone with 
activity against a variety of gram-positive bacteria, including methicillin- and 
quinolone-resistant S. aureus, as well as quinolone-resistant strains of P. aeruginosa 
or K. pneumonia 80,81].  
Its unique chemical structure facilitates improved cellular transmembrane penetration 
and potency in acidic environments common to most infectious sites. It has a novel 
mechanism of action that inhibits bacterial DNA replication by binding concurrently to 
both topoisomerase IV and DNA gyrase, in contrast to older fluoroquinolones that 
only inhibit either enzyme. The dual targeting of gyrase and topoisomerase IV 
decreases likelihood of resistance, which requires the accumulation of multiple 
mutations affecting both enzymes. This feature may contribute to the activity of 
delafloxacin against MRSA isolates, including those harboring mutations in the 
quinolone resistance determining region (QRDR) and to the low levels of resistance 
to delafloxacin among these MRSA isolates [82]. 
It also has greater affinity for DNA gyrase that older fluoroquinolones [83], which 
contributes to it having MICs that are consistently three- to five-fold lower. These 
features mean that delafloxacin not only exhibits a broader spectrum of activity but 
also confers less resistance compared to other fluoroquinolones.  
Indeed, a 2014 surveillance study revealed that all European and 98% of USA 
isolates of S. pneumoniae were inhibited at <0.03 mg/L [84], with susceptibility rates 
among USA E. coli and K. pneumoniae isolates of 65% and 78%, respectively. 
Delafloxacin is also active against P. aeruginosa (MIC50/ 90 0.25/4 mg/l; 65% 
susceptible; comparable to other anti-pseudomonal fluoroquinolones) [85] as well as 
anaerobes, atypical respiratory tract pathogens (e.g., Legionella, Chlamydia, and 
Mycoplasma), and even against M. tuberculosis. Moreover, the biofilm penetration 
capacity of has been reported to vary between 0.6% and 52%, with an acidic 
environment favoring antibiotic entry [86]. 
The bioavailability of delafloxacin is 58% when given orally and it can be dosed 
without regard to food. It is only 16% protein bound and has a half-life of 3.7 h 
following a single 300 mg intravenous dose, which ranged from 4.2 to 8.5 h following 
multiple oral doses per day. Delafloxacin shares the class characteristic of high 
pulmonary distribution with a 13:1 mean penetration ratio into the pulmonary ELF 
compared with the free plasma concentration [87].  
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The role of delafloxacin for the treatment of CAP has shown promise in two phase II 
studies. In a phase II RCT, 309 outpatients affected by CAP were treated with once 
daily oral administration of delafloxacin at different dosages (100 mg, 200 mg, or 
400 mg) for 7 days, with overall clinical and bacteriologic cure rates achieved in up to 
87% of patients. A phase III RCT (DEFINE-BCAP) has also compared delafloxacin 
with either moxifloxacin or linezolid for the treatment of adults with bacterial CAP, 
including MRSA [88]. To date, the incidence of adverse effects appears to be dose 
dependent, with diarrhea and nausea being most common; others include mild 
central nervous system effects, endocrine abnormalities, and increased serum liver 
function tests. However, no cases of clinically relevant prolongations of the QT/QTc 
interval have been reported in healthy volunteers [78]. It is also worth noting that 
delafloxacin is currently in phase III clinical development for the treatment of 
uncomplicated gonorrhea (as a single 900 mg oral dose) [89], and that phase III 
trials have determined that it is non-inferior to vancomycin or aztreonam for the 
treatment of ABSSSI [90,91]. 
In 2017, delafloxacin received FDA approval for the treatment of ABSSSIs caused by 
gram-positive and gram-negative bacteria, including MRSA, and is available in 
intravenous and oral formulations. The recommended dosage is 300 mg 
administered intravenously over 60 minutes or 450 mg administered orally every 12 
h for a maximum of 14 days [92]. Delafloxacin has been designated a QIDP by the 
FDA and has been granted fast track status for CAP once phase III trials are 
complete. 
 
5.5. The pleuromutilins: Lefamulin 
Pleuromutilin antibiotics are semisynthetic derivatives of pleuromutilin, a natural 
product of the fungi Pleurotus mutilus (now called Clitopilus scyphoides). These 
function by inhibiting bacterial protein synthesis through binding to the peptidyl 
transferase site on 23S RNA of the 50S ribosome. Retapamulin was the first agent to 
be approved by the FDA in 2006, but this was only for topical use in impetigo. 
Another pleuromutilin, tiamulin, has been used with success as a veterinary drug in 
Europe and Canada [33]. However, lefamulin is the first pleuromutilin to be 
developed for oral or intravenous use in humans.  
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Lefamulin works by binding to the 50S subunit of the bacterial ribosome at four 
distinctive binding sites in a highly conserved core of the ribosomal peptidyl 
transferase center. This unique mechanism of action also results in a lack of cross-
resistance to most currently marketed antibiotics and has inspired the development 
of analogs in an attempt to find clinically desirable derivatives [93]. Indeed, the drug 
has potent in vitro activity against organisms resistant to β-lactam antibiotics, 
fluoroquinolones, macrolides, tetracyclines, and vancomycin. 
Lefamulin achieves extensive penetration and accumulation in pulmonary epithelial 
lining fluid, with epithelial lining fluid exposure to lefamulin being 5.7-fold higher than 
the unbound fraction in plasma [94]. Ιt is 80% protein bound in the serum, has a 
biologic half-life of 12 hours, and is largely excreted unchanged via the 
gastrointestinal tract (86%), with the remainder eliminated via the kidneys (14%) [95]. 
Intravenous dosing is only required once per day, but the oral route requires dosing 
twice per day. Pharmacodynamically, it is highly potent with an MIC90 that is four-
times lower than either oxacillin, vancomycin, linezolid, or ceftaroline for S. aureus 
species (including MRSA) and many other common CAP-associated pathogens 
[96,97]. In addition, it has displayed potency against Neisseria spp., including MDR 
and extensively drug resistant N. gonorrhea isolates, supporting its potential use 
against gonorrhea [98]. 
Two phase III, noninferiority RCTs have compared the efficacy and safety of 
lefamulin with moxifloxacin for adult patients with mildly to moderately severe CAP, 
associated with PORT scores of II–IV (ClinicalTrials.gov identifier: NCT02559310 & 
NCT02813694) [99,100]. In LEAP 2, lefamulin met the primary endpoint for 
noninferiority (within 10%) set by the EMA based on investigator assessment of 
clinical response rates at 5–10 days following therapy completion in modified intent-
to-treat and clinically evaluable at test-of-cure populations [101]. The reported side 
effects mainly consist of headaches (7%), nausea (7%), and diarrhea/vomiting (4%) 
[102]. Intravenous and oral formulations of lefamulin are currently undergoing FDA 
review for use in the treatment of CAP. 
 
6. Antiviral options 
6.1. Favipiravir 
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Favipiravir is a selective and potent inhibitor of influenza viral RNA polymerase [103] 
with efficacy against all subtypes and strains of influenza (A, B and C), including 
those that are sensitive or resistant to neuraminidase and M2 inhibitors. Interestingly, 
favipiravir has antiviral activity against other RNA viruses, including Bunyaviridae, 
Arenaviridae, Filoviridae, Flaviviridae, and Picornaviridae [104-108]. In 2010, 
Sleeman et al. evaluated the in vitro ability of favipiravir to block the proliferation of 
representative influenza viruses: 2009 A(H1N1) strains,  A(H1N1) and A(H1N2) 
viruses of swine origin which were isolated from humans during 2007 and 2008, 
A(H2N2), A(H4N2), and A(H7N2), A(H5N1). This included strains that were resistant 
to either oseltamivir, zanamivir, or both, yet favipiravir retained antiviral activity 
against a wide range of influenza viruses, including the resistant ones. Currently, 
favipiravir is approved in Japan, where its use is restricted to patients infected with 
influenza virus resistant to neuraminidase inhibitors or in the event of a pandemic. 
Unfortunately, favipiravir is associated with a risk for teratogenicity and 
embryotoxicity. 
 
6.2 Pimodivir 
Pimodivir inhibits the protein basic 2 (PB2) subunit of the influenza A virus 
polymerase complex, thereby inhibiting viral replication[109]. It has in vitro activity 
against influenza A virus, including influenza pandemic 2009 H1N1, H7N9, H5N1, 
and strains resistant to neuraminidase and amantadine. Although it lacks activity 
against influenza virus B, in vitro studies have demonstrated synergy between 
pimodivir and oseltamivir. 
In a phase IIa study [110] of 104 healthy volunteers infected with an influenza virus A 
(H3N2), 72 received pimodivir and 32 received placebo. The pimodivir was given 
once daily for 5 days from 24 h after viral inoculation at doses of 100 mg, 400 mg, 
900/600 mg (as a loading dose), or 1,200/600 mg (as a loading dose). The authors 
significantly reduced viral shedding, influenza-like symptoms, and clinical symptoms 
in all dose groups compared with placebo, and that these doses were generally safe 
and well tolerated. In the subsequent phase IIb study [111], adults with acute 
uncomplicated influenza A infection were given one of the following treatments twice 
daily for 5 days: placebo, pimodivir 300 mg, pimodivir 600 mg, or pimodivir 600 mg 
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plus oseltamivir 75 mg. Pimodivir produced significant virologic improvements over 
placebo, with or without oseltamivir, showing a trend in clinical improvement and not 
serious adverse events. Currently, a phase III test among patients hospitalized with 
influenza A virus infection is ongoing. 
6.3. Presatovir 
Presatovir is an antiviral that inhibits the fusion of RSV with host cell membranes. Its 
efficacy has been demonstrated in preclinical and clinical studies [112–114], with in 
vitro activity against both major RSV strains (A and B). Studies have specifically 
reported lower viral loads after healthy volunteers infected with RSV received 
presatovir [113, 115]. Moreover, these studies have reported a favorable safety 
profile. 
 
6.4. Other agents 
Ziresovir is a fusion protein inhibitor with purported activity against RSV and is 
currently undergoing phase II clinical trials. Lumicitabine, a nucleoside analog 
prodrug, is also in clinical development. However, there is limited data on either of 
these new drugs. 
 
7. Conclusion 
CAP management requires prompt and adequate antibiotic therapy. Newly approved 
and investigational agents for the treatment of CAP hold promise that we can 
enhance our antibiotic armamentarium. However, we must first ensure that these 
new antibiotics are not only effective and well tolerated in patients but also that their 
use is kept appropriate so that we can avoid the emergence of resistance. 
 
8. Expert opinion 
Although the specific of antimicrobial therapy for CAP vary between countries, β-
lactams, fluoroquinolones, and macrolides are among the most commonly 
recommended agents. Ceftaroline, a new cephalosporine, may be considered a 
reasonable future option for empirical therapy in areas with a high prevalence of 
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MRSA or drug-resistant pathogens, rather than being kept as a reserved drug. Hope 
exists with the development of novel agents from known antibiotic classes, such as 
solithromycin (a ketolide) and zabofloxacin and delafloxacin (fluoroquinolones). 
Solithromycin benefits from having multiple binding sites in the 50S ribosome, 
making it more potent than other macrolides. Its oral formulation appears to be 
clinically effective, well tolerated, and to be suitable for once daily dosing over 5 
days. We anticipate that its development will be pursued to treat infections in 
children and pregnancy given its desirable antibacterial activities and safety profile in 
preclinical studies. Omadacycline (a newly approved cycline) offers a single-agent 
parenteral or oral alternative to traditional empirical therapy in bacterial CAP. 
Additionally, it is significantly more active than doxycycline or minocycline against 
Enterobacteriaceae and A. baumannii, and meets the FDA criterion for susceptibility 
of K. pneumoniae. Unfortunately, patients with severe CAP (Fine class V) or those 
who presented in septic shock were excluded from the RCTs of solithromycin and 
omadacycline, so we lack clinical data for their use in those patients. 
Importantly, delafloxacin could represent a highly promising option for the treatment 
of CAP based on broad-spectrum activity (including MRSA), oral formulation, 
diminished risk of resistance selection, and a favorable tolerability profile. The 
chemical structure of delafloxacin (lack of basic group in position C7) also makes it a 
non-zwitterion agent that facilitates it’s in vivo activity in acidic mediums. Together 
with its in vitro sensitivity against anaerobes, lipid solubility, and pulmonary diffusion, 
this could make it a viable empirical treatment in cases of aspiration pneumonia or 
bacterial pulmonary abscesses. However, fluoroquinolones have increasingly fallen 
from favor because of rare adverse events, including tendinopathies, neuropathies, 
and aortic dissection. On this basis, omadacycline probably represents the most 
appropriate first-choice empirical treatment for CAP. 
A major limitation of the antimicrobials described in this review is a lack of potency 
against pathogens responsible for nosocomial pneumonia. Infections caused by 
MDR P. aeruginosa, A. baumannii, and Stenotrophomonas maltophilia will therefore 
continue to pose clinical challenges because of the limited availability of potent 
antimicrobials against these gram-negative pathogens. Although there are several 
promising antibiotics in development, regulatory approval over the next five years will 
be key to any return to the availability of a more comprehensive antimicrobial 
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armamentarium that can cope with the broad spectrum of bacterial disease 
presenting in CAP. 
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TABLES 1: Antibacterial agents in the pipeline for CAP 
 
Drug Class    Drug Name         Spectrum Dose       Development 
phase for CAP 
 
Indications 
Fluoroquinolone Nemonoxacin MRSA, VRE, 
A. baumannii 
500mg /24h Phase III 
recruiting for 
i.v. 
formulation 
under US IND; 
phase III oral 
formulation 
complete 
ABSSI, 
BCAP,diabeti
c foot ulcer 
infections 
 
 Delafloxacin 
Baxdela 
Gram+ and ‒, 
including 
MRSA 
Dosage for IV 
use is 300 
mg / 12 h, 
and 450 mg 
/12h p.o. 
Phase III for 
VAP 
Approved in 
2017 for 
Acute 
bacterial skin 
and skin 
structure 
infection 
 Zabofloxacin Gram+ and ‒, 367mg/24h 
p.o. for 5 days 
Phase IΙ for 
CAP 
AECOPD 
BCAP 
Macrolide Solithromycin Gram( +), 
including 
macrolide  
resistant 
strains 
800mg 
loading dose 
and 400mg 
once a day for 
five days 
 
Phase III for 
CABP and 
uncomplicated 
gonorrhoea, in 
phase II for 
paediatric use 
ABSSSI; 
Prophylaxis 
for N. 
meningitidis;
potential for 
urethritis 
and 
other 
urogenital 
infections 
Tetracycline Omadacycline Broad 
spectrum 
incl MDR 
100mg/24h 
(i.v.) 
150mg/24h 
p.o. 
 
Phase II 
complete; 
phase III 
planned 
under FDA SPA 
FDA 
ACCEPTED 
FOR: ABSSSI 
AND BCAP 
Pleuromutilin Lefamulin Broad 
spectrum 
600mg/12h 
p.o. 
Phase III BCAP 
Cephalosporine Ceftaroline 
Teflaro 
Gram (+), 
gram (-), and 
600mg/12h 
for 10 days 
 FDA 
ACCEPTED 
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MRSA FOR :BCAP  
ABSSI: Acute bacterial skin and skin structure infection, BCAP: Bacterial community-acquired pneumonia 
 
 
 
